No business profile yet.
Size PROTEINA (468530.KS) is a South Korea Health Care company (Medical Specialties) with a market value of $460M, the 364th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩53,600 on 18 Nov 2026.
Performance Over six months the shares gained 5.1%, against -16.2% for the median peer and -37.2% for the South Korea market (cap-weighted) — 4th highest of 21 in its peer set.
Growth Revenue fell 59.5% over the last twelve months (peer median +3.9%); the operating margin is -1,178.2% (peer median 6.1%).
Valuation It trades at 26.75× book value against a peer median of 2.04× (most expensive of 21).
Price implies The share price implies a return on equity of about 70.0%; PROTEINA delivers -68.1%, so the price asks more than the business earns today.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩1.44B | ₩2.95B | ₩2.30B | ₩578M | ₩466M |
| Revenue growth | — | +28% | +298% | +24% | — |
| Gross profit | -₩502M | ₩503M | ₩942M | ₩503M | n/a |
| EBITDA | -₩15.6B | -₩10.1B | -₩8.04B | n/a | n/a |
| Net income | -₩12.0B | -₩9.01B | -₩5.73B | -₩22.8B | -₩11.4B |
| Free cash flow | -₩11.9B | -₩9.16B | -₩8.40B | -₩5.96B | -₩4.60B |
| Capital expenditure | ₩1.88B | ₩1.51B | ₩2.38B | ₩327M | ₩1.25B |
| Total debt | ₩728M | ₩867M | ₩1.01B | ₩16.7B | ₩5.70B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 468530.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +24.9% | -6.1% | 2nd highest of 21 |
| 6-month return | +5.1% | -16.2% | 4th highest of 21 |
| Return on equity | -68.1% | 1.4% | 3rd lowest of 21 |
| Price / book | 26.75× | 2.04× | most expensive of 21 |
| ROE the price implies | 70.0% | 13.1% | most demanding of 21 |
| ROE delivered | -68.1% | 1.5% | 2nd lowest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | ROE | Price / book | Implied ROE | Delivered ROE |
|---|---|---|---|---|---|---|---|---|
| PROTEINA 468530.KS | South Korea | $460M | +5% | -59% | -68% | 26.75× | 70.0% | -68.1% |
| Beijing Leadman Biochemistry 300289.SZ | China | $460M | -9% | +46% | -1% | 1.87× | 13.9% | -0.5% |
| MiMedx MDXG | United States | $464M | -16% | -23% | -9% | 2.20× | 20.4% | -8.5% |
| Eiken Chemical 4549.T | Japan | $466M | -20% | +4% | 4% | 1.68× | 10.5% | 4.2% |
| Guangdong Shirongzhaoye 002016.SZ | China | $453M | -26% | -31% | 2% | 0.61× | 4.7% | 1.8% |
| Shanghai Kindly Enterprises Development 603987.SS | China | $452M | -12% | 0% | 8% | 1.04× | 9.2% | 7.9% |
| WELL LEAD MEDICAL 603309.SS | China | $473M | -22% | +1% | 2% | 1.73× | 9.3% | 1.8% |
| Clarity Pharmaceuticals CU6.AX | Australia | $444M | -33% | n/a | -78% | 3.56× | 44.2% | -77.5% |
| AngioDynamics ANGO | United States | $476M | -4% | +8% | -19% | 2.93× | 13.4% | -19.2% |
| CellaVision CEVI.ST | Sweden | $477M | +64% | +2% | 15% | 5.20× | 21.5% | 15.5% |
| Guangdong Biolight Meditech 300246.SZ | China | $478M | -35% | +7% | -10% | 2.91× | 18.4% | -10.2% |
| Huaren Pharmaceutical 300110.SZ | China | $440M | -16% | -3% | -44% | 3.39× | 16.6% | -44.2% |
| Medprin Regenerative Medical Technologies 301033.SZ | China | $482M | -14% | +23% | 16% | 3.71× | 18.3% | 15.8% |
| Hangzhou Alltest Biotech 688606.SS | China | $484M | -20% | 0% | 3% | 0.82× | 5.4% | 3.0% |
| Guangzhou Jet Bio-Filtration 688026.SS | China | $436M | +39% | +5% | 2% | 2.33× | 22.1% | 2.0% |
| Wuhan Easy Diagnosis Biomedicine 002932.SZ | China | $485M | -14% | -9% | -1% | 0.55× | 3.1% | -1.2% |
| Mobia Medical MOBI | United States | $434M | +2% | +105% | -246% | 2.75× | 12.8% | n/a |
| Shoulder Innovations SI | United States | $432M | +39% | +55% | -25% | 3.65× | 16.0% | -25.1% |
| Zhejiang Starry Pharmaceutical 603520.SS | China | $491M | -44% | +9% | 1% | 1.33× | 11.8% | 1.1% |
| Revenio REG1V.HE | Finland | $428M | -34% | +44% | 9% | 1.74× | 11.5% | 9.1% |
| China Isotope & Radiation 1763.HK | Hong Kong | $428M | -41% | -5% | 6% | 0.58× | 5.9% | n/a |